Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1962 1
1968 1
1969 1
1973 2
1975 1
1976 3
1977 1
1978 1
1979 1
1982 1
1984 1
1985 1
1986 4
1991 2
1997 7
2000 1
2001 1
2002 1
2003 4
2004 4
2005 1
2006 2
2007 8
2008 4
2009 6
2010 1
2011 5
2012 2
2013 4
2014 3
2015 8
2016 10
2017 9
2018 13
2019 11
2020 10
2021 24
2022 30
Text availability
Article attribute
Article type
Publication date

Search Results

181 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN, Bhorat AE, du Plessis J, Esmail A, Groenewald M, Horne E, Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, Thombrayil A, van Eck S, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, Pollard AJ, de Oliveira T, Moore PL, Sigal A, Izu A; NGS-SA Group; Wits-VIDA COVID Group. Madhi SA, et al. Among authors: moore pl. N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16. N Engl J Med. 2021. PMID: 33725432 Free PMC article. Clinical Trial.
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoako DG, Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y, Jule Z, Reedoy K, Hwa SH, Giandhari J, Blackburn JM, Gosnell BI, Abdool Karim SS, Hanekom W; NGS-SA; COMMIT-KZN Team, von Gottberg A, Bhiman JN, Lessells RJ, Moosa MS, Davenport MP, de Oliveira T, Moore PL, Sigal A. Cele S, et al. Among authors: moore pl. Nature. 2022 Feb;602(7898):654-656. doi: 10.1038/s41586-021-04387-1. Epub 2021 Dec 23. Nature. 2022. PMID: 35016196 Free PMC article.
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection.
Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoako D, Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y, Jule Z, Reedoy K, Hwa SH, Giandhari J, Blackburn JM, Gosnell BI, Abdool Karim SS, Hanekom W; NGS-SA; COMMIT-KZN Team, von Gottberg A, Bhiman J, Lessells RJ, Moosa MS, Davenport MP, de Oliveira T, Moore PL, Sigal A. Cele S, et al. Among authors: moore pl. medRxiv. 2021 Dec 17:2021.12.08.21267417. doi: 10.1101/2021.12.08.21267417. Preprint. medRxiv. 2021. PMID: 34909788 Free PMC article. Updated.
T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, Khan K, Cele S, Bernstein M, Karim F, Madzorera SV, Moyo-Gwete T, Mennen M, Skelem S, Adriaanse M, Mutithu D, Aremu O, Stek C, du Bruyn E, Van Der Mescht MA, de Beer Z, de Villiers TR, Bodenstein A, van den Berg G, Mendes A, Strydom A, Venter M, Giandhari J, Naidoo Y, Pillay S, Tegally H, Grifoni A, Weiskopf D, Sette A, Wilkinson RJ, de Oliveira T, Bekker LG, Gray G, Ueckermann V, Rossouw T, Boswell MT, Bhiman JN, Moore PL, Sigal A, Ntusi NAB, Burgers WA, Riou C. Keeton R, et al. Among authors: moore pl. Nature. 2022 Mar;603(7901):488-492. doi: 10.1038/s41586-022-04460-3. Epub 2022 Jan 31. Nature. 2022. PMID: 35102311 Free PMC article.
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.
Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, Pegu A, Oloniniyi OK, Henry AR, Darko S, Narpala SR, Hatcher C, Martinez DR, Tsybovsky Y, Phung E, Abiona OM, Antia A, Cale EM, Chang LA, Choe M, Corbett KS, Davis RL, DiPiazza AT, Gordon IJ, Hait SH, Hermanus T, Kgagudi P, Laboune F, Leung K, Liu T, Mason RD, Nazzari AF, Novik L, O'Connell S, O'Dell S, Olia AS, Schmidt SD, Stephens T, Stringham CD, Talana CA, Teng IT, Wagner DA, Widge AT, Zhang B, Roederer M, Ledgerwood JE, Ruckwardt TJ, Gaudinski MR, Moore PL, Doria-Rose NA, Baric RS, Graham BS, McDermott AB, Douek DC, Kwong PD, Mascola JR, Sullivan NJ, Misasi J. Wang L, et al. Among authors: moore pl. Science. 2021 Aug 13;373(6556):eabh1766. doi: 10.1126/science.abh1766. Epub 2021 Jul 1. Science. 2021. PMID: 34210892 Free PMC article.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Aley PK, Bhikha S, Hermanus T, Horne E, Jose A, Kgagudi P, Lambe T, Masenya M, Masilela M, Mkhize N, Moultrie A, Mukendi CK, Moyo-Gwete T, Nana AJ, Nzimande A, Patel F, Rhead S, Taoushanis C, Thombrayil A, van Eck S, Voysey M, Villafana TL, Vekemans J, Gilbert SC, Pollard AJ, Moore PL, Kwatra G; Wits VIDA COVID team. Madhi SA, et al. Among authors: moore pl. Lancet HIV. 2021 Sep;8(9):e568-e580. doi: 10.1016/S2352-3018(21)00157-0. Epub 2021 Aug 17. Lancet HIV. 2021. PMID: 34416193 Free PMC article. Clinical Trial.
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
Keeton R, Richardson SI, Moyo-Gwete T, Hermanus T, Tincho MB, Benede N, Manamela NP, Baguma R, Makhado Z, Ngomti A, Motlou T, Mennen M, Chinhoyi L, Skelem S, Maboreke H, Doolabh D, Iranzadeh A, Otter AD, Brooks T, Noursadeghi M, Moon JC, Grifoni A, Weiskopf D, Sette A, Blackburn J, Hsiao NY, Williamson C, Riou C, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Moore PL, Burgers WA. Keeton R, et al. Among authors: moore pl. Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5. doi: 10.1016/j.chom.2021.10.003. Epub 2021 Oct 13. Cell Host Microbe. 2021. PMID: 34688376 Free PMC article.
The antibody response in HIV-1-infected donors.
Richardson SI, Moore PL. Richardson SI, et al. Among authors: moore pl. Curr Opin HIV AIDS. 2019 Jul;14(4):233-239. doi: 10.1097/COH.0000000000000559. Curr Opin HIV AIDS. 2019. PMID: 31033730 Free PMC article. Review.
Targeting Fc effector function in vaccine design.
Richardson SI, Moore PL. Richardson SI, et al. Among authors: moore pl. Expert Opin Ther Targets. 2021 Jun;25(6):467-477. doi: 10.1080/14728222.2021.1907343. Epub 2021 Apr 6. Expert Opin Ther Targets. 2021. PMID: 33754933 Review.
Omicron - Decoupling Infection from Severe Disease.
Moore PL, Baden LR. Moore PL, et al. N Engl J Med. 2022 Apr 7;386(14):1361-1362. doi: 10.1056/NEJMe2201812. N Engl J Med. 2022. PMID: 35388673 Free PMC article. No abstract available.
181 results